Inhibitor for restenosis after percutaneous coronary arterioplasty

Assignee: Daiichi Pharmaceutical Co Ltd

•

Filing: 1993-01-14

•

Granted: —

•

Expires: 2013-01-14

📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A lowly toxic and excellent inhibitor for restenosis after percutaneous coronary arterioplasty containing as the active ingredient a compound represented by general formula (1) or (1') or a physiologically acceptable salt thereof, wherein R¹ and R² represent each independently hydrogen, halogen, trifluoromethyl, nitro, C₁₋C₆ alkyl or C₁₋C₆ alkoxy, or alternatively R¹ and R² are combined together to form methylenedioxy; R³ represents aryl, aromatic heterocycle, 5-to 7-membered cycloalkyl or 5- to 7-membered cycloalkenyl each of which may be substituted; R⁴ represents hydrogen, hydroxy, - S-glutathionyl, -S-(α-amino acyl) or aralkyl wherein the aryl group may be substituted; R⁵ represents hydrogen or C₁-C₆ alkyl, or alternatively R⁴ and R⁵ are combined together to form a single bond; Y represents oxygen or sulfur; n represents an integer of 0 to 5; and the selenium atom may be oxidized.

Inventors

👤 Kazuhisa Kodama
👤 Atsushi Hirayama
👤 Hiroyuki Daiichi Pharmaceutical Co. Ltd Masayasu

Bibliographic Details

Application Number —

Jurisdiction EP

Data Source google_patents

Last Synchronized 2026-11-08 12:36

CPC Classifications

A; A61; A61K; A61K38/00; A61K38/04; A61K38/06; A61K38/063; A61K31/00; A61K31/28; A61K31/33; A61K31/335; A61K31/357; A61K31/36; A61K31/555; A61P; A61P9/00; A61P9/08; A61P9/10

Claims Analysis

Total Claims: 2

Claim 1

Independent Claim 163 words

An inhibitor for restenosis after percutaneous coronary arterioplasty, which comprises, as an active ingredient, a compound of the following formula (1), (1') or a pharmaceutically acceptable salt thereof: wherein R¹ and R² are independently a hydrogen atom, a halogen atom, a trifluoromethyl group, a nitro group, a C1-C6 alkyl group or a C1-C6 alkoxyl group, and R¹ and R² may be linked to form a methylenedioxy group; R³ is an optionally substituted aryl group, an optionally substituted aromatic heterocyclic group, an optionally substituted 5 to 7-membered cycloalkyl or cycloalkenyl group; R⁴ is a hydrogen atom, a hydroxyl group, an -S-glutathione residue, an -S-α-amino acid residue, or an aralkyl group optionally having substituent(s) in the aryl moiety; R⁵ is a hydrogen atom or a C1-C6 alkyl group, and R⁴ and R⁵ may be linked to form a single bond; Y is an oxygen atom or a sulfur atom; n is an integer of from 0 to 5, and the selenium atom may be oxidized.

Claim 2

Dependent Claim 21 words

An inhibitor for restenosis after percutaneous coronary arterioplasty, which comprises, as an active ingredient, 2-phenyl-1,2-benzoisoselenazol-3(2H)-one or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag

Select Category

Notes (Optional)